Aug 22, 2024
|
Vertex to Participate in Upcoming September Investor Conferences
|
|
Aug 07, 2024
|
Vertex Announces CASGEVY™ Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia in England
|
|
Aug 01, 2024
|
Vertex Reports Second Quarter 2024 Financial Results
|
|
Jul 30, 2024
|
Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute Pain
|
|
Jul 02, 2024
|
Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis
|
|
Jul 01, 2024
|
Vertex to Announce Second Quarter 2024 Financial Results on August 1
|
|
Jun 21, 2024
|
Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions
|
|
Jun 14, 2024
|
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress
|
|
Jun 07, 2024
|
Vertex Presents New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA®
|
|
May 22, 2024
|
Vertex to Participate in Upcoming June Investor Conferences
|
|
May 15, 2024
|
Jennifer Schneider Elected to Vertex Board of Directors
|
|
May 06, 2024
|
Vertex Reports First Quarter 2024 Financial Results
|
|
Apr 26, 2024
|
Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older
|
|
Apr 23, 2024
|
Vertex and TreeFrog Therapeutics Announce Licensing Agreement and Collaboration to Optimize Production of Vertex’s Cell Therapies for Type 1 Diabetes
|
|
Apr 18, 2024
|
Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
|
|
Apr 10, 2024
|
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
|
|
Apr 09, 2024
|
Vertex to Announce First Quarter 2024 Financial Results on May 6
|
|
Apr 01, 2024
|
Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease
|
|
Mar 21, 2024
|
Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|
|
Feb 23, 2024
|
Vertex Receives CHMP Positive Opinion for KALYDECO® for the Treatment of Infants With Cystic Fibrosis Ages 1 Month and Older
|
|